Anzeige
Mehr »
Login
Dienstag, 24.09.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
In einem boomenden Goldmarkt ist das die Aktie, die man im Auge behalten sollte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
665 Leser
Artikel bewerten:
(2)

Rackspace Technology, Inc.: Rackspace Technology Works with Biomedical Software Company inPhronesis to Modernize Email Infrastructure and Optimize its Knowledge Management Portal

With Microsoft 365, inPhronesis, manages the data and intelligence that drives the management of pharmaceutical companies

SAN ANTONIO, April 03, 2023® to modernize the company's email infrastructure and optimize the knowledge management portal. The biomedical software expert manages the data and intelligence that drives the management of pharmaceutical companies with Microsoft 365.

inPhronesis was designed by Competitive Intelligence (CI) consultants to track large amounts of ever-changing data for competitive and Business Intelligence (BI) inside the Pharma and Biomedical industries. The company's mission is to offer clients a streamlined interface with custom functionality for their business intelligence. The software development company was founded in 2019 in Orlando, Florida, to allow users to configure enterprise-level solutions that make their customers' lives easier.

inPhronesis' main product is a software called inVision, which delivers essential insights into the biomedical industry. The application is a hub of client information used by over 3,500 pharmaceutical and medical technology professionals to stay up to date on the industry. The system sends out multiple daily alerts reporting on different markets, classes of drugs, and advancements at various companies.

Rackspace Technology was tasked with helping the inPhronesis IT team map out a plan for integrating dozens of different applications and tools and account for managing mobile Windows iOS, and Android devices used by employees in the field.

"inPhronesis underwent a SOC 2 certification process. For a small business, ensuring compliance and improving data security can be complex, with many moving parts. For this reason, inPhronesis wanted the flexible service delivery model available through Rackspace Elastic Engineering," said Eric Tapley, IT director at inPhronesis. "There are so many different pieces and so much to know. Because we had Rackspace Elastic Engineering, we knew that we could come up with any question on any part of it. We weren't siloed into doing just one project."

As a data platform trusted by eight top 20 global pharmaceutical companies, inPhronesis wanted to deploy Microsoft 365 and optimize security to address SOC 2 compliance requirements. "There's a ton of things to get done and rolling out Microsoft Intune for device management is a big chunk of that work. Having Rackspace Technology to help was invaluable," said Tapley.

"One of the Rackspace team's first tasks was helping the inPhronesis IT team map out a plan for integrating dozens of different applications and tools. This plan needed to account for managing mobile Windows, iOS and Android devices used by employees in the field. Microsoft Intune solved for the endpoint management challenges while Microsoft 365 helped to account for data security and audit capabilities.," said Josh Prewitt, President of Private Cloud for Rackspace Technology. "Throughout the audit process, inPhronesis resolved obstacles at a moment's notice. When there was an issue with OneDrive synchronization or a question on settings for Outlook, inPhronesis brought it to their Rackspace Elastic Engineering team."

After working closely with Rackspace Technology, inPhronesis deployed Microsoft 365, enabled endpoint management, and adjusted security settings in time for the SOC 2 audit. The company now has a certification showing it complies with five trust principles and is safeguarding proprietary data for clients. Today, inPhronesis is in an even better position to attract new clients and prove its dedication to loyal partners.

"There's a ton of things to get done and rolling out Microsoft Intune for device management is a big chunk of that work. Having Rackspace Technology to help was invaluable," said Tapley.

Click hereto read more about Rackspace Technology and the inPhronesis solution.

About Rackspace Technology
Rackspace Technologyis a leading end-to-end multicloud technology services company. We can design, build and operate our customers' cloud environments across all major technology platforms, irrespective of technology stack or deployment model. We partner with our customers at every stage of their cloud journey, enabling them to modernize applications, build new products and adopt innovative technologies.

Media Contact
Natalie Silva
publicrelations@rackspace.com


© 2023 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.